Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
69.28M | 69.56M | 209.91M | 33.92M | 0.00 | Gross Profit |
63.33M | 67.03M | 205.33M | 32.52M | -1.97M | EBIT |
-130.65M | -165.99M | -123.63M | -261.72M | -219.26M | EBITDA |
-103.71M | -146.76M | -108.06M | -223.72M | -219.26M | Net Income Common Stockholders |
-157.85M | -240.05M | -155.80M | -230.03M | -246.29M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
250.87M | 278.60M | 326.44M | 466.54M | 439.19M | Total Assets |
321.98M | 354.78M | 529.17M | 617.97M | 513.69M | Total Debt |
123.00M | 124.38M | 117.38M | 101.75M | 41.87M | Net Debt |
-127.87M | -154.22M | -209.07M | -364.79M | -397.32M | Total Liabilities |
524.62M | 503.03M | 440.44M | 451.88M | 178.19M | Stockholders Equity |
-202.64M | -148.25M | 88.73M | 166.09M | 335.50M |
Cash Flow | Free Cash Flow | |||
-124.70M | -121.90M | -139.09M | -239.75M | -171.54M | Operating Cash Flow |
-123.83M | -118.69M | -136.79M | -233.38M | -168.73M | Investing Cash Flow |
-867.00K | -3.22M | -2.51M | -6.67M | -2.83M | Financing Cash Flow |
97.05M | 73.88M | -593.00K | 267.39M | 494.97M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
55 Neutral | $241.00M | ― | 123.38% | ― | 10.49% | 47.31% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
49 Neutral | $119.73M | ― | -50.77% | ― | ― | -54.29% | |
49 Neutral | $238.99M | ― | -99.23% | ― | -40.10% | -16.60% | |
39 Underperform | $162.72M | ― | -75.60% | ― | ― | -2.29% | |
36 Underperform | $123.62M | ― | -244.16% | ― | ― | 77.12% | |
28 Underperform | $46.70M | ― | -41.96% | ― | ― | 72.12% |
ADC Therapeutics announced preliminary information on ZYNLONTA’s net sales and expenses for 2024, showcasing stabilized sales despite increased competition and achieving profitability for the brand. The company has implemented a disciplined portfolio management strategy, resulting in a double-digit cost reduction for the second consecutive year, and anticipates a cash runway into mid-2026, positioning itself strongly in the ADC market.